Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Escalon MedicalESMC 34 ROC (Joel Greenblatt) % is 485.60% as of Mar. 2026. GuruFocus rates ESMC with a GF Score™ of 34/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Escalon Medical ranks better than 96.9% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Escalon Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 485.60%.
The historical rank and industry rank for Escalon Medical's ROC (Joel Greenblatt) % or its related term are showing as below:
ESMC'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -73.26 Med: -3.48 Max: 99.76
Current: 99.76
During the past 13 years, Escalon Medical's highest ROC (Joel Greenblatt) % was 99.76%. The lowest was -73.26%. And the median was -3.48%.
ESMC's ROC (Joel Greenblatt) % is ranked better than 96.9% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs ESMC: 99.76
Escalon Medical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Escalon Medical (OTCPK:ESMC) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Escalon Medical ROC (Joel Greenblatt) % Related Terms
Escalon Medical ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Escalon Medical's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESMC vs RBOT, NUWE, NUMD: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Escalon Medical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Escalon Medical ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Escalon Medical's ROC (Joel Greenblatt) % falls into.
Escalon Medical ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 485.60% mean?
Escalon Medical (ESMC) has a ROC (Joel Greenblatt) % of 485.60% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Escalon Medical and its competitors. According to the industry distribution chart, Escalon Medical ranks #26 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 3.1%.
Is Escalon Medical's ROC (Joel Greenblatt) % too high?
Escalon Medical's current ROC (Joel Greenblatt) % is 485.60%. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Escalon Medical's value of 485.60% is 11615.3% above this industry median. Based on the distribution chart, Escalon Medical ranks #26 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Escalon Medical has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Escalon Medical's ROC (Joel Greenblatt) % compare to RBOT and NUWE?
According to the Medical Devices & Instruments industry distribution chart, Escalon Medical ranks #26 out of 838 companies for ROC (Joel Greenblatt) %. This places Escalon Medical in the top 3% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Escalon Medical's value of 485.60% is 11615.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Escalon Medical's current ROC (Joel Greenblatt) % of 485.60% is 11615.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Escalon Medical and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Escalon Medical's current ROC (Joel Greenblatt) % is 485.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Escalon Medical stock overvalued right now?
Based on GuruFocus' analysis, Escalon Medical (ESMC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.20 — trading 33.3% above its estimated fair value. The current ROC (Joel Greenblatt) % is 485.60% and 11615.3% above the Medical Devices & Instruments industry median of 4.15. Escalon Medical's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Escalon Medical (ESMC), the current ROC (Joel Greenblatt) % is 485.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Escalon Medical (ESMC) Overvalued in 2026?
Based on GuruFocus' analysis, Escalon Medical stock appears to be overvalued.
The current stock price of $0.20 is trading 33.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Escalon Medical to be Significantly Overvalued.
Key valuation signals for ESMC:
ROC (Joel Greenblatt) %: 485.60%
GF Value™: $0.15 vs. price of $0.20 (33.3% above fair value)
Industry Position: 11615.3% above the Medical Devices & Instruments median (#26 of 838)
No single metric tells the full story. See the ESMC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Escalon Medical Corp operates in the healthcare market, specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. Its products are A-Scans, B-Scans, UBM, Pachymeters, Ispan Intraocular Gases, Surgical Packs, Viscous Fluid Transfer Systems, and AXIS Image Management. Substantial revenue is generated from the domestic sales of products.
34GF Score
Get the complete analysis for ESMC
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESMC has been successfully added to your 
